• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pharmacokinetics of intramuscularly administered ertapenem.肌内注射厄他培南的药代动力学。
Antimicrob Agents Chemother. 2003 May;47(5):1732-5. doi: 10.1128/AAC.47.5.1732-1735.2003.
2
Pharmacokinetics of ertapenem in healthy young volunteers.厄他培南在健康年轻志愿者中的药代动力学。
Antimicrob Agents Chemother. 2002 Nov;46(11):3506-11. doi: 10.1128/AAC.46.11.3506-3511.2002.
3
Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects.健康老年受试者中厄他培南总药物及游离药物的药代动力学
Antimicrob Agents Chemother. 2004 Feb;48(2):521-4. doi: 10.1128/AAC.48.2.521-524.2004.
4
Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers.健康成年志愿者中,每日 1 克厄他培南快速输注 5 分钟与标准输注 30 分钟的药代动力学、药效学和耐受性比较。
Pharmacotherapy. 2013 Mar;33(3):266-74. doi: 10.1002/phar.1197. Epub 2013 Feb 11.
5
Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers.厄他培南(一种每日给药一次的肠外碳青霉烯类药物)在健康年轻志愿者吸入诱导的皮肤水疱液中的组织穿透情况。
Antimicrob Agents Chemother. 2003 Apr;47(4):1439-42. doi: 10.1128/AAC.47.4.1439-1442.2003.
6
Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis.厄他培南每日一次给药在重症脓毒症危重症患者中的药代动力学
Int J Antimicrob Agents. 2009 May;33(5):432-6. doi: 10.1016/j.ijantimicag.2008.10.005. Epub 2008 Dec 16.
7
Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone.利多卡因稀释后肌内注射厄他培南的安全性和局部耐受性:一项与肌内注射头孢曲松对比的前瞻性、随机、双盲研究。
Clin Ther. 2002 Mar;24(3):434-44. doi: 10.1016/s0149-2918(02)85044-5.
8
A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia.一项关于静脉注射厄他培南与头孢曲松治疗社区获得性肺炎住院成人患者的前瞻性、随机、双盲多中心比较研究。
Clin Ther. 2002 Nov;24(11):1770-85. doi: 10.1016/s0149-2918(02)80078-9.
9
Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents.单次静脉注射厄他培南在婴儿、儿童和青少年中的药代动力学和耐受性。
Pediatr Infect Dis J. 2010 Dec;29(12):1072-6. doi: 10.1097/INF.0b013e3181e82608.
10
Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients.药代动力学和最佳剂量厄他培南在间歇性血液透析患者中的研究。
Nephrol Dial Transplant. 2019 Oct 1;34(10):1766-1772. doi: 10.1093/ndt/gfy166.

引用本文的文献

1
Model for Evaluating Antimicrobial Therapy To Prevent Life-Threatening Bacterial Infections following Exposure to a Medically Significant Radiation Dose.评估抗菌治疗以预防因暴露于医学意义上的辐射剂量后发生危及生命的细菌感染的模型。
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0054622. doi: 10.1128/aac.00546-22. Epub 2022 Sep 26.
2
Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against .贝那配南通过模型指导药物研发、药代动力学/药效学截断值确定及其对 的抗菌疗效
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01751-19.
3
Lung abscess in an immunocompromised patient: clinical presentation and management challenges.免疫功能低下患者的肺脓肿:临床表现及管理挑战
BMJ Case Rep. 2019 Jul 16;12(7):e230756. doi: 10.1136/bcr-2019-230756.
4
Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.结核病患者中 2000 毫克厄他培南的药代动力学。
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02250-17. Print 2018 May.
5
Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.降阶梯治疗至厄他培南用于治疗产超广谱β-内酰胺酶肠杆菌科细菌所致感染的疗效与安全性:一项开放标签随机对照试验
BMC Infect Dis. 2017 Mar 1;17(1):183. doi: 10.1186/s12879-017-2284-1.
6
Ertapenem: a review of its use in the treatment of bacterial infections.厄他培南:其在治疗细菌感染中的应用综述
Drugs. 2005;65(15):2151-78. doi: 10.2165/00003495-200565150-00013.
7
Ertapenem: a review of its use in the management of bacterial infections.厄他培南:对其在细菌感染治疗中应用的综述。
Drugs. 2003;63(17):1855-78. doi: 10.2165/00003495-200363170-00006.

本文引用的文献

1
Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.厄他培南每日一次与哌拉西林-他唑巴坦每日4次用于治疗成人复杂性皮肤及皮肤结构感染:一项前瞻性、随机、双盲多中心研究的结果
Clin Infect Dis. 2002 Jun 1;34(11):1460-8. doi: 10.1086/340348. Epub 2002 May 9.
2
A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.一项评估厄他培南与头孢曲松治疗成人社区获得性肺炎的疗效、安全性及耐受性的研究。
Clin Infect Dis. 2002 Apr 15;34(8):1076-83. doi: 10.1086/339543. Epub 2002 Mar 18.
3
Dose-dependent plasma clearance of MK-826, a carbapenem antibiotic, arising from concentration-dependent plasma protein binding in rats and monkeys.
J Pharm Sci. 1999 Feb;88(2):277-80. doi: 10.1021/js980232k.
4
High-performance liquid chromatographic methods for the determination of a new carbapenem antibiotic, L-749,345, in human plasma and urine.
J Chromatogr B Biomed Sci Appl. 1998 Dec 11;720(1-2):99-106. doi: 10.1016/s0378-4347(98)00437-x.
5
In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345).新型长效碳青霉烯类抗生素MK-826(L-749,345)的体内活性及药代动力学评价
Antimicrob Agents Chemother. 1998 Aug;42(8):1996-2001. doi: 10.1128/AAC.42.8.1996.
6
Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates.长效碳青霉烯类抗生素L-749,345在灵长类动物中的药代动力学
Antimicrob Agents Chemother. 1997 Aug;41(8):1743-8. doi: 10.1128/AAC.41.8.1743.
7
Estimation of variance for harmonic mean half-lives.调和平均半衰期的方差估计。
J Pharm Sci. 1985 Feb;74(2):229-31. doi: 10.1002/jps.2600740229.

肌内注射厄他培南的药代动力学。

Pharmacokinetics of intramuscularly administered ertapenem.

作者信息

Musson Donald G, Majumdar Anup, Birk Kimberly, Holland Sherry, Wickersham Peter, Li Susan X, Mistry Goutam, Fisher Alison, Waldman Scott, Greenberg Howard, Deutsch Paul, Rogers J Douglas

机构信息

Merck Research Laboratories, West Point, Pennsylvania 19486, USA.

出版信息

Antimicrob Agents Chemother. 2003 May;47(5):1732-5. doi: 10.1128/AAC.47.5.1732-1735.2003.

DOI:10.1128/AAC.47.5.1732-1735.2003
PMID:12709348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC153313/
Abstract

Ertapenem (INVANZ) is a new once-a-day parental beta-lactam antimicrobial agent that has been shown to be highly effective as a single agent for treatment of various community-acquired and mixed infections. The plasma pharmacokinetics of a 1-g intramuscular (i.m.) dose was compared with those of a 1-g intravenous (i.v.) dose infused over 30 min, the recommended rate of i.v. infusion for comparison, and over 120 min, which more closely mimicked the time course for absorption of the i.m. form. In a three-period crossover study (Part A), 26 healthy subjects received single doses of ertapenem administered i.m., i.v. infused over 30 min, and i.v. infused over 120 min. Blood for ertapenem analysis was collected over 24 h postdose for each treatment. In Part B, these fasted subjects received a 1-g i.m. dose of ertapenem once daily for 7 days. Following a 1-g i.m. dose and a 1-g i.v. dose infused over 120 min, the geometric mean area under the concentration curve from hour 0 to infinity (AUC(0- infinity )) was 541.8 micro g. hr/ml following i.m. administration and 591.4 micro g. hr/ml following a 120-min infusion; the geometric mean ratio was 0.92 with a 90% confidence interval of 0.88 to 0.95. The geometric mean AUC(0- infinity ) was nearly identical when 1-g doses were infused over 30 or 120 min. Although the maximum concentration of drug in serum was somewhat lower following i.m. administration than following i.v. administration, the shape of the plasma concentration profiles was roughly comparable at later time points. Ertapenem did not accumulate after multiple 1-g i.m. daily doses over 7 days. The geometric mean ratio for AUC(0-24) (day 7/day 1) was 0.98 with a 90% confidence interval of 0.94 to 1.02. Thus, the relative bioavailability of the 1-g i.m. dose was 92%. Ertapenem does not accumulate following multiple daily 1-g i.m. doses over 7 days.

摘要

厄他培南(怡万之)是一种新型的每日一次的肠外β-内酰胺类抗菌药物,已被证明作为单一药物治疗各种社区获得性感染和混合感染时具有高效性。将1克肌内注射(i.m.)剂量的血浆药代动力学与1克静脉注射(i.v.)剂量在30分钟内输注(推荐的静脉输注速率用于比较)以及在120分钟内输注(更接近肌内注射剂型的吸收时间过程)的药代动力学进行了比较。在一项三期交叉研究(A部分)中,26名健康受试者接受了单剂量的厄他培南,分别为肌内注射、在30分钟内静脉输注以及在120分钟内静脉输注。每种治疗给药后24小时内采集血样进行厄他培南分析。在B部分,这些空腹受试者每天接受1克肌内注射剂量的厄他培南,共7天。在1克肌内注射剂量和在120分钟内输注1克静脉注射剂量后,从0小时到无穷大的浓度曲线下几何平均面积(AUC(0 - ∞))在肌内注射给药后为541.8微克·小时/毫升,在120分钟输注后为591.4微克·小时/毫升;几何平均比值为0.92,90%置信区间为0.88至0.95。当1克剂量在30分钟或120分钟内输注时,几何平均AUC(0 - ∞)几乎相同。尽管肌内注射给药后血清中药物的最大浓度略低于静脉注射给药后,但在后期时间点血浆浓度曲线的形状大致相当。在7天内每日多次1克肌内注射剂量后,厄他培南没有蓄积。AUC(0 - 24)(第7天/第1天)的几何平均比值为0.98,90%置信区间为0.94至1.02。因此,1克肌内注射剂量的相对生物利用度为92%。在7天内每日多次1克肌内注射剂量后,厄他培南不会蓄积。